Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-53...
October 16 2017 - 7:30AM
Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced presentations at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics, taking place October 26-30, 2017 in
Philadelphia.
A late-breaking poster will be presented on Saturday, October
28, by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center and
will feature data from Kura’s recently-announced positive Phase 2
proof-of-concept trial in head and neck squamous cell carcinoma
(HNSCC) with HRAS mutations. In addition, the poster has been
selected as the subject of a short, oral presentation during the
Spotlight on Proffered Papers Session 1 on Friday, October 27.
A second late-breaking poster will be presented on Saturday,
October 28, and will feature preclinical data for KO-539, Kura’s
potent and selective inhibitor of the menin-MLL interaction,
supporting the potential clinical utility of KO-539 in NPM1- and
DNMT3A-mutant AML.
The schedule and locations for the late-breaking oral
presentation and poster presentations is as follows:
Oral Presentation:
Title of Presentation: Preliminary results from a Phase 2
proof-of-concept trial of tipifarnib in tumors with HRAS
mutationsDate & Time: Friday, October 27, 2017, 10:50 a.m. -
12:20 p.m. EDTPresenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan
Kettering Cancer CenterSession: Spotlight on Proffered Papers
Session 1Location: Terrace Ballroom, 400 Level, Pennsylvania
Convention Center
Poster Presentations:
Title of Poster: Preliminary results from a Phase 2
proof-of-concept trial of tipifarnib in tumors with HRAS
mutationsDate & Time: Saturday, October 28, 12:30 p.m. – 4:00
p.m. EDTPresenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan
Kettering Cancer CenterSession: Late-Breaking Poster Session A
(Clinical Trials)Abstract Number: LB-A10Location: Hall E,
Pennsylvania Convention Center
Title of Poster: A novel small molecule menin-MLL inhibitor for
potential treatment of MLL-rearranged leukemias and
NPM1/DNMT3A-mutant AMLDate & Time: Saturday, October 28, 12:30
p.m. – 4:00 p.m. EDTPresenter: Francis Burrows, Ph.D., Kura
OncologyLate-Breaking Poster Session A (Epigenetic Targets)Abstract
Number: LB-A27Location: Hall E, Pennsylvania Convention Center
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials. Kura’s pipeline
also includes KO-947, an ERK inhibitor, currently in a Phase 1
trial, and KO-539, an inhibitor of the menin-MLL protein-protein
interaction, currently in preclinical testing. For additional
information about Kura Oncology, please visit the company’s website
at www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and therapeutic
potential of tipifarnib and KO-539, progress and expected timing of
Kura Oncology’s drug development programs and clinical trials and
plans regarding future clinical trials and development activities.
Factors that may cause actual results to differ materially include
the risk that compounds that appeared promising in early research
or clinical trials do not demonstrate safety and/or efficacy in
later preclinical studies or clinical trials, the risk that Kura
Oncology may not obtain approval to market its product candidates,
uncertainties associated with performing clinical trials,
regulatory filings and applications, risks associated with reliance
on third parties to successfully conduct clinical trials, the risks
associated with reliance on outside financing to meet capital
requirements, and other risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "promise, "
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to the Company's periodic and other
filings with the Securities and Exchange Commission, which are
available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Kura Oncology
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT INFORMATION
INVESTOR CONTACT:Robert H. UhlManaging
DirectorWestwicke Partners, LLC(858)
356-5932robert.uhl@westwicke.com
MEDIA CONTACT:Mark CorbaeVice PresidentCanale
Communications(619) 849-5375mark@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024